scholarly journals A Case of Myeloma Kidney With Glomerular C3 Deposition

2018 ◽  
Vol 7 (3-4) ◽  
pp. 73-77
Author(s):  
Asif Khan ◽  
Khine Lam ◽  
Suzanne El-Sayegh ◽  
Elie El-Charabaty
Keyword(s):  
Myeloma Kidney

O-24 AUTOLOGOUS HEMOPOIETIC PROGENITOR CELL COLLECTION IN TANDEM WITH HEMODIALYSIS IN A PATIENT WITH MYELOMA KIDNEY

2012 ◽  
Vol 47 ◽  
pp. S12-S13
Author(s):  
R. Weinstein ◽  
J. Linden ◽  
G. Laplante ◽  
N. Banks ◽  
G. Kershaw ◽  
...  
Keyword(s):  
Progenitor Cell ◽  
Myeloma Kidney ◽  
O 24 ◽  
Hemopoietic Progenitor

A069 FLC Removal HD Improves Outcomes in Myeloma Kidney

2009 ◽  
Vol 9 ◽  
pp. S10-S11
Author(s):  
M Cook ◽  
C Hutchison ◽  
S Basu ◽  
P Cockwell ◽  
AR Bradwell
Keyword(s):  
Myeloma Kidney

Role of plasmapheresis in the management of myeloma kidney: A systematic review

2010 ◽  
Vol 14 (4) ◽  
pp. 355-363 ◽  
Author(s):  
Diptesh GUPTA ◽  
Lohith BACHEGOWDA ◽  
Gautam PHADKE ◽  
Sue BOREN ◽  
Diane JOHNSON ◽  
...  
Keyword(s):  
Systematic Review ◽  
Myeloma Kidney

The patient with myeloma

2018 ◽  
Author(s):  
Efstathios Kastritis ◽  
Meletios A. Dimopoulos
Keyword(s):  
Renal Impairment ◽  
Renal Dysfunction ◽  
Significant Proportion ◽  
Early Death ◽  
New Drugs ◽  
Light Chains ◽  
High Dose ◽  
Myeloma Kidney ◽  
High Doses ◽  
High Dose Melphalan

Renal impairment is a common feature of multiple myeloma and often the presenting symptom of a patient with symptomatic myeloma. ‘Myeloma kidney’ results from the excess of immunoglobulin light chains which form aggregates and casts that result in tubular obstruction; however, light chains may cause renal damage with a variety of mechanisms, which often may coexist in the same patient. The presence of significant renal dysfunction in a patient with myeloma is associated with a risk for significant complications, including early death. Myeloma kidney is usually associated with high tumour burden and high rates of paraprotein production.Patients with renal impairment should be managed immediately with appropriate antimyeloma therapy and supported vigorously. New drugs such as bortezomib are probably the most effective therapies for patients with renal dysfunction and may improve renal function in a significant proportion of patients with myeloma-related renal impairment, especially with dexamethasone at high doses. Other drugs such as thalidomide or lenalidomide may also be helpful in certain patients. Direct removal of the toxic free light chains may improve outcomes in some patients, but randomized studies are still ongoing. The role of plasmapheresis has not been established.Autologous stem cell transplantation, with appropriate dose adjustments for high-dose melphalan should be offered in eligible patients, even those on dialysis, although this procedure may be associated with a higher risk of toxicity in patients with more severe renal dysfunction. Renal transplantation may be an option for selected patients who have responded well to therapy.

SP462ACUTE MYELOMA KIDNEY: EFFICACY OF DOUBLE FILTER BASED EXTRACORPOREAL TREATMENTS COMBINED TO CHEMOTHERAPY FOR PATIENT AND KIDNEY SURVIVAL

2019 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Fulvia Zappulo ◽  
Gabriele Donati ◽  
Anna Laura Croci Chiocchini ◽  
Anna Scrivo ◽  
Elisa Maietti ◽  
...  
Keyword(s):  
Myeloma Kidney

A new form of myeloma “kidney”: shortened hemofilter survival and implications for membrane filtration plasmapheresis

2011 ◽  
Vol 75 (02) ◽  
pp. 120-124 ◽  
Author(s):  
A.-P. Dana ◽  
C.A. Ahmar ◽  
W.L. Clapp ◽  
E.A. Ross
Keyword(s):  
Membrane Filtration ◽  
New Form ◽  
Myeloma Kidney
Sign in / Sign up

Export Citation Format

Share Document